Given the critical role of PARP inhibitors in selectively killing tumor cells with HRD features, they have emerged as a promising therapeutic strategy whose indications have been expanded from germline BRCA1/2-mutated to HRD breast cancer [108]. Here, BRCA1 is linked to breast carcinoma.